Safety and Efficacy of Oral Cladribine in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the 96 Week Phase IIIb Extension Trial to the CLARITY Study

被引：0

作者：

Giovannoni, Gavin ^{[1
]}

Comi, Giancarlo ^{[2
]}

Cook, Stuart ^{[3
]}

Rammohan, Kottil ^{[4
]}

Rieckmann, Peter ^{[5
]}

Soelberg-Sorensen, Per ^{[6
]}

Vermersch, Patrick ^{[7
]}

Hamlett, Anthony ^{[8
]}

Scaramozza, Matthew ^{[9
]}

Lachenal, Nathalie ^{[10
]}

机构：

[1] Barts & London Queen Marys Sch Med & Dent, Blizard Inst, London, England

[2] Inst Expt Neurol, Milan, Italy

[3] Univ Med & Dent New Jersey, Newark, NJ 07103 USA

[4] Ohio State Univ, Miami, FL USA

[5] Dept Neurol, Bamberg, Germany

[6] Danish MS Ctr, Copenhagen, Denmark

[7] Univ Lille, Lille, France

[8] EMD Serono Inc, Rockland, NY USA

[9] EMD Serono Inc, Rockland, MA USA

[10] Merck Serono, Geneva, Switzerland

来源：

NEUROLOGY | 2013年 / 80卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P07119

引用

页数：2

共 50 条

[1] Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
Giovannoni, Gavin
Sorensen, Per Soelberg
Cook, Stuart
Rammohan, Kottil
Rieckmann, Peter
Comi, Giancarlo
Dangond, Fernando
Adeniji, Abidemi K.
Vermersch, Patrick
[J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (12) : 1594 - 1604
[2] Safety and Tolerability of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study
Cook, Stuart
Comi, Giancarlo
Rieckmann, Peter
Rammohan, Kottil
Soelberg-Soerensenn, Per
Vermersch, Patrick
Martin, Emily
Dangond, Fernando
Giovannoni, Gavin
[J]. NEUROLOGY, 2016, 86
[3] Safety and tolerability of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS): final results from the 120-week Phase IIIb extension trial to the CLARITY study
Cook, S.
Comi, G.
Rieckmann, P.
Rammohan, K.
Soelberg-Sorensen, P.
Vermersch, P.
Martin, E.
Dangond, F.
Giovannoni, G.
[J]. SWISS MEDICAL WEEKLY, 2016, 146 : 78S - 78S
[4] Clinical efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS): final results from the 120-week Phase IIIb extension trial to the CLARITY study
Giovannoni, G.
Comi, G.
Cook, S.
Rieckmann, P.
Rammohan, K.
Soelberg-Sorensen, P.
Vermersch, P.
Martin, E.
Dangond, F.
[J]. SWISS MEDICAL WEEKLY, 2016, 146 : 79S - 79S
[5] Clinical Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results fro the 120-Week Phase IIIb Extension Trial to the CLARITY Study
Giovannoni, Gavin
Comi, Giancarlo
Cook, Stuart
Rieckmann, Peter
Rammohan, Kottil
Soelberg-Soerensenn, Per
Vermersch, Patrick
Martin, Emily
Dangond, Fernando
[J]. NEUROLOGY, 2016, 86
[6] Safety and Efficacy of Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis in Patients with High Disease Activity: Results from the Phase III, 96-Week CLARITY Study
Rammohan, Kottil
Comi, Giancarlo
Cook, Stuart
Giovannoni, Gavin
Rieckmann, Peter
Sorensen, Per Soelberg
Vermersch, Patrick
Kurukulasuriya, Nuwan C.
Chang, Peter
Greenberg, Steven J.
[J]. NEUROLOGY, 2011, 76 (09) : A612 - A613
[7] Safety of cladribine tablets for relapsing-remitting multiple sclerosis in patients with high disease activity: results from the phase III, 96-week CLARITY study
Rammohan, K.
Comi, G.
Cook, S.
Giovannoni, G.
Rieckmann, P.
Sorensen, P. Soelberg
Vermersch, P.
Kurukulasuriya, N.
Bischof, D.
Chang, P.
Greenberg, S.
[J]. JOURNAL OF NEUROLOGY, 2011, 258 : 259 - 259
[8] Efficacy of cladribine tablets for relapsing-remitting multiple sclerosis in patients with high disease activity: results from the phase III, 96-week CLARITY study
Rammohan, K.
Comi, G.
Cook, S.
Giovannoni, G.
Rieckmann, P.
Sorensen, P. Soelberg
Vermersch, P.
Kurukulasuriya, N.
Chang, P.
Greenberg, S.
[J]. JOURNAL OF NEUROLOGY, 2011, 258 : 21 - 21
[9] Efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS) in the 120-week extension to the CLARITY study
Giovannoni, Gavin
Comi, Giancarlo
Cook, Stuart
Rieckmann, Peter
Rammohan, Kottil
Soelberg-Soerensen, Per
Vermersch, Patrick
Martin, Emily
Dangond, Fernando
[J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP6 - NP7
[10] Oral cladribine in relapsing-remitting multiple sclerosis: study design of the 2-year, Phase IIIb CLARITY (CLAdRIbine tablets Treating multiple sclerosis orallY) extension study
Giovannoni, G.
Cook, S.
Greenberg, S.
Chang, P.
Comi, G.
Rieckmann, P.
Sorensen, P. Soelberg
Vermersch, P.
[J]. JOURNAL OF NEUROLOGY, 2008, 255 : 206 - 206

← 1 2 3 4 5 →